--- a
+++ b/clusters/9knumclustersv2/clust_1378.txt
@@ -0,0 +1,26 @@
+Cardiovascular Risks as outlined in the protocol.
+Understand study design, risks, and benefits and have signed informed consent
+Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study; a legal guardian may substitute for the research participant
+Subject must understand risks and benefits of the protocol and be able to give informed consent
+Failure of research participant or legally responsible parent or guardian to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study.
+Unable to understand the purpose and risks of the study
+Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study; a legal guardian may substitute for the research participant
+Understand the study purpose, requirements, and risks
+Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study
+Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study
+Patients should be in such a health condition in the opinion of the attending physician that with the administration of mifepristone benefits may outweigh risks
+Subjects must be able to understand the potential risks and benefits of the study, and be able to read and give written informed consent
+Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study; a legal guardian may substitute for the research participant
+Understands the potential risks and benefits of study participation and is willing to provide written informed consent.
+Known thrombophilic risk factors. Exception: Subjects for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator
+Ability to understand the purpose and risks of the study.
+Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study
+Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study
+Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this pilot study; a legal guardian may substitute for the research participant
+Understands study design, risks, and benefits and have signed informed consent
+Patients with known thrombophilic risk factors; exception: patients for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator
+Able to comprehend the full nature and purpose of the study, including possible risks and side effects.
+Inability to understand the risks and benefits of the study
+Patient Volunteers: Inability to understand the risks and benefits of the study
+Patient Volunteers/Contrast Enhancement Sub-group: Inability to understand the risks and benefits of the study
+PHASE I: Women that answer  or more of the questions about the benefits and risks of the study incorrectly will be excluded